ID: MRFR/Pharma/1731-CR | January 2019 | Region: Global | 124 pages
The Antihypertensive Drugs Market size can touch USD 41,123.2 Million by 2023, according to the extensive research conducted by Market Research Future (MRFR). MRFR identifies the rising number of awareness campaigns by governmental and non-profit organizations across the world as one of the reasons for market growth.
Antihypertensive drugs market share has declined owing to the lockdown imposed following the COVID-19 outbreak. The novel coronavirus pandemic has reduced the number of cardiac surgeries in view of the re-scheduling, no-show by patients, cancellations and lower consultations in the wake of restrictions by health authorities and government. In view of the steadily growing number of SARS-CoV-2 cases, only emergency services are currently being allowed, while the decrease in heart disease hospital admissions has slowed down the market growth.
However, MRFR experts believe that the market could be resilient over the forthcoming period. This can be the case since latest studies show that COVID-19 patients are dealing with sevaerl cardiovascular complications, and as a result, health authorities are encouraging the use of CVD drugs and antihypertensive drugs. This could ensure sustainable market growth in the years to follow. Surging popularity of e-commerce and online drug stores will also result in antihypertensive drugs market expansion during the review period, despite the escalating novel coronavirus cases.
Antihypertensive Drugs Market Dynamics
Escalating Hypertension Cases Worldwide to Push Market Growth
One of the foremost growth rendering factors in the antihypertensive drugs market is the alarming rise in incidences of hypertension across countries. The growing cases are also raising the awareness level among the mass about the complications related to hypertension, which also encourages market growth. The consistently expanding geriatric pool across the globe along with the high prevalence of sedentary lifestyle fosters major growth as well. The mounting need for early diagnosis as well as treatment of hypertension is bolstering the demand for antihypertensive drugs in the market. Some of the modern anti-hypertensive drugs in the market that are used for treatment include ACE inhibitors, vasodilators and diuretics. However, these antihypertensive drugs in pregnancy are advised to be avoided so as not to give way to any complications.
Rising Preference for Combination Therapy to Offer Opportunities
Of late, combination therapies have witnessed significant applications compared to the monotherapy form of treatment. Monotherapy involves the use of a single drug, whereas combination therapy facilitates action on multiple hypertensive mechanisms. The latter involves combining two drugs that have varying mechanisms of action, which leads to an effect that is much higher than monotherapy.
Combination therapy helps bring down cerebrovascular events by 54% and coronary issues by 40%. Therefore, combination therapy offers better protection to the organ with lower dose compared to monotherapy and its wide acceptance across the world is proving to be a lucrative opportunity for leading firms in the global industry.
Lower Awareness Levels in Developing Countries to be a Key Restraint
Lower awareness levels with regard to antihypertensive drugs amongst the mass in developing countries can be a huge restraint in the worldwide market. A vast population in developing countries tends to neglect health-checkups and has low knowledge about hypertension conditions and symptoms, which is making it hard for players to gain any profits in these regions.
Patients with hypertension generally do not adhere to the required medication schedule and tend to stop medications in only 1 to 2 weeks, which gives rise to the symptoms again. This passive attitude of patients is posing a significant challenge to the firms in the anti-hypertensive drugs industry. For instance, in 2016, BMC Research conducted a research that stated that only 17% of 112 hypertensive individuals with stroke adhered to antihypertensive drugs and medications.
Cumulative Growth Analysis
Introduction of New Treatment Options to Bolster Market’s Growth Rate
The antihypertensive drugs market growth is expected to be at a rate of 2.67% over the analysis period (between 2015 and 2023), on account of the rising introduction of new antihypertensive therapy options.
Antihypertensive Drugs Market Segment Overview
Cost Effectiveness to Bolster Demand for Beta Blockers
MRFR’s review of anti-hypertensive drugs market outlines a few key therapeutic classes, namely beta-adrenergic blockers, calcium channel blockers, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, renin inhibitors, diuretics, vasodilators, and others. Latest studies have concluded that antihypertensive drugs beta blockers and diuretics are far more cost-effective compared to other therapeutic classes and therefore, observe considerable demand in the antihypertensive drugs market.
Secondary Hypertension-Based Drugs to observe Strong demand
Depending on the type of anti-hypertensive drugs in the antihypertensive drugs market are primary as well as secondary. Secondary hypertension segment is in the lead owing to early diagnosis, faster detection, surging cases of thyroid problems, chronic alcohol use, kidney problems, heart ailments, adrenal gland tumors and more. However, the antihypertensive drugs classification by MRFR also reveals that the segmental growth can be slowed down by patent expiries including United Therapeutic's Remodulin (2014) and Actelion's Tracleer (2015).
E-Commerce Websites and Online Drug Stores Gain Massive Popularity
Distribution channels highlighted in the MRFR study are retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others. E-commerce websites and online drug stores segment can expect to surge forward at the fastest rate over the evaluation period, on account of the high internet usage and popularity of smartphones and tablets.
Antihypertensive Drugs Market Regional Analysis
America to Reach the Leading Position in the Coming Years
AHA or American heart association claims that close to 74.9% of the total hypertension patients in North America are being treated while only about 52.2% of them have it under control. AHA also projects that by the year 2030; roughly 41.4% of individuals in the US/United States will suffer from hypertension. These scaling numbers indicate the bright growth prospects of the American market for antihypertensive drugs. Also, the mounting need for accurate and prompt diagnosis as well as treatment of hypertension, detecting people that are predisposed to the disorder and the presence of modern healthcare infrastructure also work in favor of the American anti-hypertension industry. The orthostatic hypotension drugs market has been growing exponentially in the region, with a soaring number of patients suffering from low blood pressure.
APAC Races Ahead at the Fastest Rate as China and India Take the Lead
MRFR anticipates the APAC antihypertensive drugs market to exhibit the fastest growth during the conjectured period, thanks to the soaring awareness level about antihypertensive drugs and other treatment options. The stunning growth of the life science industry in India, Malaysia and China has also been an important growth booster in the APAC market. The anti-hypertensive drugs rhabdomyolysis are gaining traction in the region, in view of the surge in alcohol abuse, rising intake of toxic substances and overexertion. The rising availability of various categories of anti-hypertensive drugs in the region and growing access to these also promote market expansion. The growth of the antihypertensive drugs market in India can be directly linked to the rising consumption of unhealthy or junk food, lack of balanced and healthy diet, improper sleep owing to irregular working hours that result in hypertension. These factors have amplified the rate of diseases like stroke, heart failure, chronic kidney disease, peripheral vascular disease and more.
Antihypertensive Drugs Market Competitive Landscape
Significant Investments by Players to Intensify Competition
Anti-hypertensive drugs market is quite stable, since it is rife with several affluent firms. The expected market growth rate is sluggish owing to the rising use of generic drugs. Substantial spending by leading manufacturers in developing new drugs and medicines is a major trend that can continue throughout the review period. Prominent growth strategies that are primarily employed by the top vendors in the market include agreement, product launch, acquisition, expansion and partnership.
Merck is an eminent antihypertensive drug brand that aims to produce medicines as well as vaccines for highly challenging disorders. The company is known for its commitment to the global population’s health by enabling patients to have access to advanced healthcare via far-reaching programs, policies, and partnerships. Merck has also always been at the forefront of extensive researches for preventing and treatment of various diseases, which also include hypertensive disorders.
List of Key Companies Covered in this Report
Scope of the Report
The scope of the report highlights drivers, opportunities, restraints and challenges surrounding the global market. With easy-to-comprehend segmentation that includes antihypertensive drugs classification, therapeutic class, distribution channel, as well as region, MRFR projections are on the basis of historical as well as expected trends. Major firms active in the global market have been profiled as well, paired with the top strategies employed by them to remain competitive in the industry.
|Market Size||USD 41,123.2 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Therapeutic Class, Type and Distribution Channel|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Sanofi S.A., Takeda Pharmaceuticals Company Limited, Boehringer Ingelheim, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited Inc., Daiichi Sankyo Company Limited, Astra Zeneca plc, Acetelion Ltd|
|Key Market Opportunities||Rising Preference for Combination Therapy to Offer Opportunities|
|Key Market Drivers||Escalating Hypertension Cases Worldwide to Push Market Growth|
Frequently Asked Questions (FAQ) :
Antihypertensive Drugs Market can grow up to a valuation of USD 41,123.2 million by 2023.
Antihypertensive Drugs Market would grow with a valuation of 2.67% CAGR during the forecast period of 2018 to 2023.
Antihypertensive Drugs Market has distribution channels like retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others.
Americas has a maximum Antihypertensive Drug Market growth.
Long-term high blood pressure is the primary antihypertensive drugs, market driver.
Antihypertensive Drugs Market: Company Landscape
There are numerous large and small players operating in the global antihypertensive drugs market. Owing to the loss of patents of major branded antihypertensive drugs in the recent years, many players have entered into the market with generic drugs which has led to the significant loss of market share of major players operating in the market.
Some prominent players in the global antihypertensive drugs market are Novartis AG, United Therapeutics Corporation, Daiichi Sankyo Company, Ltd, Sanofi, Bayer AG, Boehringer Ingelheim GmbH, AstraZeneca Plc among others.
Novartis AG is one of the leading players in the global antihypertensive drugs market. The share of the company is due to its antihypertensive its products Diovan/Co-Diovan and Exforge. The company’s share was affected by the high genericization of its antihypertensive drugs. Novartis AG has strong brand name along with extensive global presence. The company is currently focusing in development of new products to increase its revenue generation. Moreover, the company is also engaged in strategic collaborations and mergers to strengthen its position in the pharmaceutical segment.
United Therapeutics Corporation is one of the prominent players in the global antihypertensive drugs market. The company has decent product portfolio for pulmonary arterial hypertension (PAH). United Therapeutics Corporation has strong market penetration in the US market. The company has increased its focus on expanding its business in the international market.
Daiichi Sankyo Company, Ltd, a renowned company in the global antihypertensive drugs market, is engaged in strategic merger activities which has helped in strengthening its brand image. The company is involved in developing new drugs for treating hypertension which is expected to increase its market revenue in the coming years. For instance, in September 2017, the company announced that the Phase 3 study for Esaxerenone for treatment of essential hypertension in Japan was successful and showed positive outcomes.
Apart from these companies, there are large number of companies operating in this market. The other players include Hikma Pharmaceuticals, Amneal Pharmaceuticals LLC, Upsher-Smith Laboratories, LLC, Apotex Corporation, Aa Pharma Inc., Salix Pharmaceuticals, Ipca Laboratories Limited, Ranbaxy Inc., Macleods Pharmaceuticals Limited, Jamp Pharma Corporation, Wockhardt USA LLC., and Glenmark Pharmaceuticals Inc.